{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:37:57Z","timestamp":1787665077511,"version":"build-2736575974"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>This study assessed the adverse drug reactions (ADRs) associated with HDAC inhibitors using the VigiAccess database maintained by the World Health Organization (WHO). Furthermore, it compared the ADR profiles of three different drugs to identify the one with the lowest individualized risk for patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>Data on adverse events of HDAC Inhibitors was retrieved from WHO-VigiAccess on 6 January 2025. We obtained data on age, gender, reporting year, and continent. Descriptive data related were calculated using Excel 2021. In this study, we used Excel software to analyze the characteristics of those who were harmed due to adverse reactions. For each drug, the reporting rate of adverse reactions was calculated by dividing the number of adverse reaction symptoms of this drug by the total number of adverse reaction reports. We listed the top 20 most frequent adverse reaction symptoms as common adverse reactions. By counting the frequency and proportion of these common adverse reactions, we conducted a comparative analysis of the adverse reaction situations of different drugs and classified them according to different types.<\/jats:p><\/jats:sec><jats:sec><jats:title>Result<\/jats:title><jats:p>The WHO-VigiAccess database received 796, 1254, and 1658 ADR reports for Chidamide, Romidepsin, and Vorinostat respectively by 2024, with a total of 3,708. Gender distribution was relatively balanced (male:female ratio 0.81:1), and the 45\u201364 age group had the highest reporting rates, mostly from the Americas. Chidamide had higher rates in certain disorders, Romidepsin in others, and Vorinostat in specific ones. Common ADRs included thrombocytopenia etc., with some differences in rates among drugs. Serious ADR proportions were 0% for Chidamide, 2.27% for Romidepsin, and 1.02% for Vorinostat. 37 common signals were found, with Investigations having the most. Each drug had different ADR preferred terms (PTs) in renal\/urinary and metabolism\/nutrition disorders, with varying numbers of distinctive symptoms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Current comparative observational studies of these inhibitors indicate that there are both common and specific adverse reactions reported in the ADR data received by the WHO for these medications. Clinicians should enhance the rational use of these drugs by considering the characteristics of the reported ADRs.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1563797","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T07:05:28Z","timestamp":1742281528000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Characteristic analysis of adverse reactions of histone deacetylase inhibitors based on WHO-VigiAccess"],"prefix":"10.3389","volume":"16","author":[{"given":"Tongnan","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenwen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinran","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumeng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongyu","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1200\/JCO.2006.09.8293","article-title":"Addition of histone deacetylase inhibitors in combination therapy","volume":"25","author":"Carraway","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3322\/caac.21765","article-title":"Cancer epigenetics in clinical practice","volume":"73","author":"Davalos","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"B4","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41568-020-0247-0","article-title":"Peripheral T cell lymphomas: from the bench to the clinic","volume":"20","author":"Fiore","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/sj.cr.7310149","article-title":"HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics","volume":"17","author":"Gallinari","year":"2007","journal-title":"Cell Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.3390\/ijms23073538","article-title":"Epigenetics of cutaneous T-cell lymphomas","volume":"23","author":"Hara","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s11899-010-0067-5","article-title":"The emerging role of histone deacetylase inhibitors in treating T-cell lymphomas","volume":"6","author":"Horwitz","year":"2011","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"B8","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.3390\/cancers16193359","article-title":"Histone deacetylase inhibitors for peripheral T-cell lymphomas","volume":"16","author":"Irimia","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/nrc.2016.82","article-title":"Metabolic control of epigenetics in cancer","volume":"16","author":"Kinnaird","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/S1470-2045(11)70327-8","article-title":"Histone deacetylase inhibitors and Hodgkin's lymphoma","volume":"12","author":"Kirschbaum","year":"2011","journal-title":"Lancet Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2174\/1568026619666190122144949","article-title":"Zinc-dependent deacetylase (HDAC) inhibitors with different zinc binding groups","volume":"19","author":"Li","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"key":"B12","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1080\/13543776.2023.2219393","article-title":"An updated patent review of histone deacetylase (HDAC) inhibitors in cancer (2020 - present)","volume":"33","author":"Liu","year":"2023","journal-title":"Expert Opin. Ther. Pat."},{"key":"B13","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13148-023-01531-8","article-title":"Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL)","volume":"15","author":"Lu","year":"2023","journal-title":"Clin. Epigenetics"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e1600584","DOI":"10.1126\/sciadv.1600584","article-title":"Epigenetics and aging","volume":"2","author":"Pal","year":"2016","journal-title":"Sci. Adv."},{"key":"B15","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.blre.2016.02.002","article-title":"Epigenetics: a primer for clinicians","volume":"30","author":"Paluch","year":"2016","journal-title":"Blood Rev."},{"key":"B16","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s12276-020-0382-4","article-title":"A short guide to histone deacetylases including recent progress on class II enzymes","volume":"52","author":"Park","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2174\/1568009622666220624090542","article-title":"Recent progress in histone deacetylase (HDAC) 1 inhibitors as anticancer agent","volume":"23","author":"Patel","year":"2022","journal-title":"Curr. Cancer Drug Targets"},{"key":"B18","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1146\/annurev-pathol-020117-043821","article-title":"Pathogenesis of peripheral T cell lymphoma","volume":"13","author":"Pizzi","year":"2018","journal-title":"Annu. Rev. Pathol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.2174\/0929867327666200203113926","article-title":"Romidepsin (FK228), A histone deacetylase inhibitor and its analogues in cancer chemotherapy","volume":"28","author":"Pojani","year":"2021","journal-title":"Curr. Med. Chem."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/S1470-2045(13)70425-X","article-title":"Histone deacetylase inhibitors in multiple myeloma","volume":"14","author":"Pratt","year":"2013","journal-title":"Lancet Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.3390\/diagnostics12082001","article-title":"Pathological and molecular features of nodal peripheral T-cell lymphomas","volume":"12","author":"Satou","year":"2022","journal-title":"Diagn. (Basel)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40264-018-0773-9","article-title":"Safety and tolerability of histone deacetylase (HDAC) inhibitors in oncology","volume":"42","author":"Shah","year":"2019","journal-title":"Drug Saf."},{"key":"B23","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/bs.pmbts.2023.02.011","article-title":"Histone deacetylase (HDACs) inhibitors: clinical applications","volume":"198","author":"Shanmukha","year":"2023","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"424","DOI":"10.7150\/ijms.30154","article-title":"Histone deacetylases (HDACs) guided novel therapies for T-cell lymphomas","volume":"16","author":"Zhang","year":"2019","journal-title":"Int. J. Med. Sci."},{"key":"B25","first-page":"e74","article-title":"Peripheral T-cell lymphomas: incorporating new developments in diagnostics, prognostication, and treatment into clinical practice-PART 1: PTCL-NOS, FTCL, AITL, ALCL","volume":"32","author":"Zing","year":"2018","journal-title":"Oncol. Willist. Park"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1563797\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T07:05:31Z","timestamp":1742281531000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1563797\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":25,"alternative-id":["10.3389\/fphar.2025.1563797"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1563797","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,18]]},"article-number":"1563797"}}